The Immunogenicity and Safety of Inactivated Trivalent Split Influenza Vaccine in

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Influenza Vaccines

  2012cited by this paper
• Optimizing immunization in pediatric special risk groups

  2011cited by this paper
• Vaccination coverage and risk factors for incomplete vaccination in children with recurrent wheeze.

  2011cited by this paper
• Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence.

  2010cited by this paper
• Long-term outcomes of early childhood wheezing

  2009cited by this paper
• Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.

  2006cited by this paper
• Strategy for distribution of influenza vaccine to high-risk groups and children.

  2005cited by this paper
• A Comparison of 2 Influenza Vaccine Schedules in 6- to 23-Month-Old Children

  2005cited by this paper
• Inactivated influenza virus vaccines in children.

  2004cited by this paper
• Immunogenicity and protective efficacy of influenza vaccination.

  2004cited by this paper
• Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children

  2004cited by this paper
• Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial.

  2003cited by this paper
• Influenza in children: the German perspective

  2003cited by this paper
• Influenza burden in children newborn to eleven months of age in a pediatric emergency department during the peak of an influenza epidemic

  2003cited by this paper
• Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children.

  2002cited by this paper
• The incidence of influenza-associated hospitalizations in children in Germany

  2002cited by this paper
• Rapid antibody response to influenza vaccination in "at risk" groups.

  2000cited by this paper
• The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.

  2000cited by this paper
• Safety and immunogenicity of a paediatric presentation of an influenza vaccine

  2000cited by this paper
• Effect of prednisone on response to influenza virus vaccine in asthmatic children.

  1998cited by this paper
• Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users.

  1997cited by this paper
• Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids.

  1996cited by this paper
• Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy.

  1996cited by this paper
• Asthma and wheezing in the first six years of life. The Group Health Medical Associates.

  1995cited by this paper
• Bronchial asthma after early childhood wheezing: a follow‐up until 4.5–6 years of age

  1994cited by this paper
• Evaluation of the Efficacy of Split‐Product Trivalent A(H1N1), A(H3N2), and B Influenza Vaccines

  1986cited by this paper
• Evaluation of the Efficacy of Split‐Product Trivalent A(H1N1), A(H3N2), and B Influenza Vaccines

  1986cited by this paper
• Glucocorticosteroids I: anti-inflammatory mechanisms.

  1983cited by this paper
• Safety of influenza vaccination in allergic children.

  1977cited by this paper
• Corticosteroids and immunoglobulin synthesis.

  1975cited by this paper
• ANTIBODY RESPONSES TO ANTIGENIC DETERMINANTS OF INFLUENZA VIRUS HEMAGGLUTININ

  1974cited by this paper

• No citing papers are available for this paper.